You are here

New AAN Guideline on Treatment of Chorea in Huntington’s Disease

Huntington’s disease is a complex disorder with physical, cognitive, and behavioral symptoms. The new guideline addresses only one aspect of the disease that may require treatment.

“Chorea can be disabling, worsen weight loss, and increase the risk of falling,” said Melissa Armstrong, MD, MSc, the guideline’s lead author. According to the new statement, tetrabenazine (TBZ), riluzole, and amantadine may be helpful for treating chorea, and nabilone may also be considered. Riluzole, amantadine, and nabilone are not often prescribed for Huntington’s disease.

“People with Huntington’s disease who have chorea should discuss with their doctors whether treating chorea is a priority,” Dr. Armstrong said “Huntington’s disease is complex, with a wide range of sometimes severe symptoms, and treating other symptoms may be a higher priority than treating chorea.”

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug